Text Size

Correlation of clinical symptoms and signs with conjunctival gene expression in primary Sjögren syndrome dry eye patients

Liang H., Kessal K., Rabut G., Daull P., Garrigue J.S., Melik Parsadaniantz S., Docquier M., Baudouin C., Brignole-Baudouin F.


  • 2019
  • Ocular Surface
View publication
  • Therapeutic Area

    Front of the eye (FOTE)

  • Affiliations

    Sorbonne Universités, UPMC Univ Paris 06, INSERM, CNRS, Institut de la Vision, Paris, France; Quinze-Vingts National Ophthalmology Hospital, DHU Sight Restore, INSERM-DHOS CIC1423, Paris, France; Santen SAS, Evry, France; iGE3 Genomics Platform University of Geneva, Geneva, Switzerland; Université Versailles-Saint-Quentin-en-Yvelines, UVSQ, Hôpital Ambroise Paré, APHP, Boulogne-Billancourt, France; Université Sorbonne Paris Cité USPC, Université Paris Descartes, Faculté de Pharmacie de Paris, France

Related Publications

Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (NOVATIVE): A Phase II/III, Multicenter, Double-masked, Randomized Study of 0.05% Cyclosporine A and 0.1% Ophthalmic Cationic Emulsion Versus Vehicle in Patients With Vernal Keratoconjunctivitis

Leonardi A, Pisella PJ, Benítez-Del-Castillo JM, Amrane M, Ismail D, Doan S, Bremond-Gignac D.


Correlation between gene expression and clinical scores in vernal keratoconjunctivitis

Leonardi A, Cavarzeran F, Rosani U, Righetti G, Garrigue JS, Brun P.


Topical cyclosporine A cationic ophthalmic emulsion in paediatric vernal keratoconjunctivitis: pooled analysis of randomised NOVATIVE and VEKTIS trials

Leonardi A, Doan S, Aragona P,  Amrane M, Ismail D, Montero J, Németh J, Bremond-Gignac D


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022